Revenue of $621.4 million , an increase of $110.4 million or 21.
6% , from the three months ended September 30, 2023 . Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.
2) million and a net loss margin of (5.0)% . Adjusted EBITDA of $31.
8 million resulting in an Adjusted EBITDA margin of 5.1% . Revises outlook for Adjusted EBITDA for 2024.
Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets. Announces record six new contract agreements in the quarter. WASHINGTON , Nov.
7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH ), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended September 30, 2024. Seth Blackley , co-founder and Chief Executive Officer of Evolent stated, "In the face of significant shifts in medical expenses experienced in the managed care industry, we believe the need for Evolent's solutions is very high – a belief supported by our record new business announcements during the quarter.
Outside of our Performance Suite, our diversified business is performing at or better than our expectations. Despite the clinical value we believe our solutions create, our third quarter Adjusted EBITDA result was negatively impacted by losses in our Performance Suite, driven both by new information from our partners regarding claims paid in prior.
